BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
89.75
+5.70 (+6.78%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close84.05
Open86.75
Bid0.00 x 900
Ask0.00 x 800
Day's Range85.14 - 90.74
52 Week Range71.42 - 163.43
Volume2333477
Avg. Volume1,103,588
Market Cap5B
Beta (5Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-13.00
Earnings DateFeb 19, 2020 - Feb 24, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est142.94
  • Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting
    MarketWatch

    Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting

    A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.

  • Is bluebird bio Inc (BLUE) Going to Burn These Hedge Funds?
    Insider Monkey

    Is bluebird bio Inc (BLUE) Going to Burn These Hedge Funds?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September […]

  • Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
    Zacks

    Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

    The biotech sector witnesses pipeline updates from the annual ASH meet.

  • Barrons.com

    Bluebird bio Is ‘Remarkably Undervalued,’ Analyst Says

    Bluebird bio is set to start earning money from drug sales next year, and SVB Leerink analyst Mani Foroohar is increasing his price target on the stock.

  • Fate (FATE) Announces Encouraging Data on Immunotherapies
    Zacks

    Fate (FATE) Announces Encouraging Data on Immunotherapies

    Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

  • Business Wire

    bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

    bluebird bio and BMS announce updated results from the ongoing Phase 1 study (CRB-402) of bb21217 in Relapsed and Refractory Multiple Myeloma at ASH

  • Business Wire

    bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin™ Gene Therapy for β-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition

    bluebird bio, Inc. announced new data from ongoing studies of LentiGlobin™ gene therapy for β-thalassemia at the 61st ASH Annual Meeting.

  • bluebird Reports Positive Top-Line Data on Myeloma Drug
    Zacks

    bluebird Reports Positive Top-Line Data on Myeloma Drug

    bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.

  • 5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP
    InvestorPlace

    5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP

    Stocks slipped slightly on Monday as investors work off some of Friday's jobs report rally and as trade-war headlines continue to pop up. Let's look at a few top stock trades as we kick off the week. Top Stock Trades for Tomorrow No. 1: Chewy (CHWY)Source: Chart courtesy of StockCharts.comChewy (NYSE:CHWY) is set to report earnings after the close Monday, as are our Top Trades No. 2 and 3.Over the last few trading sessions, CHWY stock has fought hard to break out over downtrend resistance (blue line). To its credit, Chewy stock has done a good job holding up over this mark, although it struggled in Monday's session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAfter the company reports after the close, it's vital that the stock doesn't go on to make new lows below $21.68. If it does, it puts $20 -- and possibly the teens -- on the table. Ideally though, CHWY will hold up over the 20-day moving average at $23.57, as well as downtrend resistance. * 7 Overlooked Value Stocks to Buy That Will Shine in 2020 On the upside, let's see if CHWY can clear some of the clutter near current levels. Specifically, let's see if it can clear the 50-day moving average and the $25 level. Above that puts the 78.6% retracement just below $26 on the table. Moving above all of these levels puts the declining 100-day moving average near $28 on the table. Top Stock Trades for Tomorrow No. 2: Toll Brothers (TOL)Source: Chart courtesy of StockCharts.comI have routinely highlighted Toll Brothers (NYSE:TOL) as a relative strength leader. The stock has a pattern of ripping to new highs, consolidating its gains and rallying to new highs again.Can it do it again on earnings?TOL stock is trying to break out over the $41.50 level. See if it can get above and more importantly, stay above this level after its post-earnings reaction. If it can, a breakout maybe in the making.On a decline, see where support comes into play. Can TOL hold its 20-day and 50-day moving averages near $40? How about uptrend support (blue line) near $39.50? Falling below the pattern puts $38.50 on the table. Below that and the 200-day moving average is possible. Top Stock Trades for Tomorrow No. 3: Stitch Fix (SFIX)Source: Chart courtesy of StockCharts.comStitch Fix (NASDAQ:SFIX) shares made an impressive move Monday, breaking out over $24. Of course, the whole move could be for naught, depending on the post-earnings reaction.On a pullback, it would be ideal for SFIX stock to hold this $24 breakout level as support. But given SFIX's history of volatility, that's also unlikely. So on the downside, let's see if $22 can hold as support. There it has short-term uptrend support (blue line), as well as the 100-day moving average. Further, its 50-day moving average sits at $22.28. Below this area could put $18 on the table.On the upside, let's see if SFIX can reclaim its 50% retracement near $26.90. Above that puts the 61.8% retracement on the table. Top Stock Trades for Tomorrow No. 4: Bluebird bio (BLUE)Source: Chart courtesy of StockCharts.comIt has been a tough run for bluebird bio (NASDAQ:BLUE), as highlighted by Monday's 2.7% decline. In late November, BLUE broke out over downtrend resistance (blue line), but found $85 and the 50-day moving average to be resistance.After Monday's pullback, the backside of that downtrend mark buoyed the share price. For bulls, the setup is now simple.On the downside, prior downtrend resistance and the $72 level have to hold as support. On the upside, bulls need to reclaim $85 and the 50-day moving average. Top Stock Trades for Tomorrow No. 5: Shopify (SHOP)Source: Chart courtesy of StockCharts.comShopify (NASDAQ:SHOP) has been getting a lot of attention lately and deservedly so.Again, keep this one as simple as you can. Recent resistance has come into play at $375. Above it opens the door to $400. At the same time, recent support has come into play near $360. Below it puts $340 on the table. Below that and the 50-day moving average will be key.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks That Are Still Worth Buying In 2020 * 7 Strong Stocks to Buy That Won Q3 Earnings * 5 Safety Stocks to Buy Without Trade War Exposure The post 5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP appeared first on InvestorPlace.

  • Barrons.com

    Bluebird Bio Stock Is Rising on Promising Cancer-Drug Data

    Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.

  • Business Wire

    bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

    bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at ASH Annual Meeting

  • Bloomberg

    Bluebird, Celgene Cancer Therapy Gets Boost From New Study

    (Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high-dose infusion of the personalized medicine known as bb2121 generated a response in 44 of 54 patients with multiple myeloma, including 19 who had a complete response, the companies said in a statement Friday. Patients went a median of 11.3 months before the cancer progressed, topping expectations that it needed to stop the disease for at least six months to gain approval from the U.S. Food and Drug Administration.Bluebird shares briefly jumped in late trading on Friday before surrendering most of their gains. The recently-issued CVR given in connection with the closing of Bristol-Myers’ deal with Celgene, known by the ticker BMY-R, rose 8.3%.The companies divulged the findings on the eve of the American Society of Hematology’s annual meeting in Orlando, Florida, where GlaxoSmithKline Plc., Regeneron Pharmaceuticals Inc. and Bristol’s own Celgene unit will present data on competing approaches. Cambridge, Massachusetts-based Bluebird and New York-based Bristol-Myers are scheduled to give an update on their next-generation therapy, bb21217, on Monday, while hotly anticipated results from competitor Johnson & Johnson’s Nanjing Legend Biotech-partnered therapy will take the spotlight that morning.The depth and the durability of the data “puts us in very good stead around any of the antibodies as well as other gene therapies,” Bluebird Chief Executive Officer Nick Leschly said. “We feel quite good about it, and that’s why we’re sprinting toward submission and driving toward earlier lines of therapy.”Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note. A response rate greater than 80% that can hold off the disease for at least 11 months would be well-received by doctors who might otherwise be wary of potential high costs and an aggressive approach, said Yaron Werber, an analyst at Cowen & Co.The approach known as CAR-T is already approved for a hard-to-treat form of pediatric leukemia and diffuse large B cell lymphoma, both blood cancers that are much less common than the multiple myeloma, which is diagnosed in about 30,000 Americans each year. Bluebird and Bristol’s therapy involves removing infection-fighting T cells from the blood, altering them to recognize a protein known as BCMA that is found in multiple myeloma cells, then putting them back into the patient to kill the cancer.(Updates with stock-price movement in third paragraph)\--With assistance from Tatiana Darie.To contact the reporters on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.net;Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Mark Schoifet, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Business Wire

    Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

    BMS and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

  • Zacks

    Stocks Rebound and Hang Onto Recent Gains

    Stocks Rebound and Hang Onto Recent Gains

  • Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?

    Investors need to pay close attention to bluebird (BLUE) stock based on the movements in the options market lately.

  • Business Wire

    bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

    bluebird bio, Inc. (BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology Annual Meeting and Exposition. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event.

  • Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD
    Zacks

    Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD

    Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.

  • Barrons.com

    Bluebird Bio Stock Is Rising as Analyst Cites Room for Gains

    Analysts at SVB Leerink upgraded the stock to Outperform, saying that its recent downturn creates an opportunity to buy.

  • CRISPR Therapeutics stock jumps on early gene editing data
    American City Business Journals

    CRISPR Therapeutics stock jumps on early gene editing data

    CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.

  • Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease
    Zacks

    Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease

    Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.

  • Business Wire

    bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

    bluebird bio, Inc. (BLUE) and Forty Seven, Inc. (FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with bluebird’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy platform. This collaboration will focus on a conditioning approach aimed to deliver reduced toxicity and will initially target diseases that have the potential to be corrected with transplantation of autologous gene-modified blood-forming stem cells.

  • FDA approves Acceleron's blood disorder drug ahead of schedule
    American City Business Journals

    FDA approves Acceleron's blood disorder drug ahead of schedule

    Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.

  • American City Business Journals

    These 36 Mass. firms made Deloitte's Technology Fast 500

    Massachusetts is home to 36 of the 500 companies making this year’s ranking, with three local firms making the top 100 — including the No. 2 spot.

  • Business Wire

    bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

    Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma

  • Companies Like bluebird bio (NASDAQ:BLUE) Are In A Position To Invest In Growth
    Simply Wall St.

    Companies Like bluebird bio (NASDAQ:BLUE) Are In A Position To Invest In Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...